Phaseline

Targets › CD30

CD30 (Tumor necrosis factor receptor superfamily member 8): drug programs, companies and trials

9 programs from 6 companies in 17 trials: 15 Phase 1, 2 Phase 2; Oncology; next expected readout Apr 2027.

Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. (UniProt, P28908)

Open in Phaseline: the race on CD30, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
UNC Lineberger Comprehensive Cancer CenterATLCAR.CD30.CCR4 cells
CD30-targeted CAR-T cell therapy
CD30Phase 2Peripheral T Cell Lymphoma; Hodgkin Lymphoma; Hodgkin Disease; LymphomaFeb 2028
Tessa TherapeuticsAutologous CD30.CAR-T
CD30-directed CAR-T cell therapy
CD30Phase 2Hodgkin Lymphoma, Adult; Anaplastic Large Cell Lymphoma; Classical Hodgkin LymphomaMar 2036
Baylor College of MedicineC7R.CD30.CAR-EBVST cells
Allogeneic CD30 chimeric antigen receptor (CAR) T cells with constitutive IL7R signaling d
CD30Phase 1Hodgkin's Lymphoma; Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type; CD30-Positive Diffuse Large B-Cell LymphomaApr 2027
Beijing BiotechEB-CAR30-NK
CD30-targeted allogeneic CAR-NK cells
CD30Phase 1B2 ThymomaJun 2027
Ruijin HospitalLCAR-HL30
CD30-targeted CAR-T cell therapy
CD30Phase 1Hodgkin's LymphomaAug 2028
Chinese PLA General HospitalCD30-targeting CAR-T Cell Therapy
Chimeric antigen receptor T cell therapy targeting CD30
CD30Phase 1LymphomaAug 2028
Chinese PLA General HospitalCART30
anti-CD30 CAR T cell therapy
CD30Phase 1Hodgkin's LymphomaOct 2029
Baylor College of Medicineautologous CAR.CD30 EBV specific-CTLs
CD30-targeted chimeric antigen receptor T cell therapy; EBV-specific CTLs engineered to ex
CD30Phase 1Hodgkin's LymphomaOct 2033
UNC Lineberger Comprehensive Cancer CenterALTCAR.CD30 cells
CD30-targeted CAR-T cells
CD30Phase 1LymphomaNov 2039

Conditions

Hodgkin's Lymphoma (4) Lymphoma (4) Hodgkin Lymphoma, Adult (1) Anaplastic Large Cell Lymphoma (1) Classical Hodgkin Lymphoma (1) Peripheral T Cell Lymphoma (1) Hodgkin Lymphoma (1) Hodgkin Disease (1) B2 Thymoma (1) Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type (1) CD30-Positive Diffuse Large B-Cell Lymphoma (1)

Modalities

mixed (4), other (3), protein or peptide (1), small molecule (1)

Companies

Chinese PLA General Hospital (2) Baylor College of Medicine (2) UNC Lineberger Comprehensive Cancer Center (2) Tessa Therapeutics (1) Ruijin Hospital (1) Beijing Biotech (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.